Deepbridge Capital's Andrew Aldridge, Partner & Chief of Marketing has recently been featured in Professional Adviser's article where he speaks on deciding what to do to help protect client's wealth being the conundrum of the year as inflation spikes.
Deepbridge are pleased to announce that we have appointed Simon Thellwall-Jones to the newly created role of Venture Partner.
Aquarate Ltd, which is part of the Deepbridge Life Sciences EIS fund, has recently announced a new partnership with Wirral Council to offer digital hydration monitoring across care homes.
Compono, an investee company within the Deepbridge Technology Growth EIS portfolio, has appointed Trent Innes, former Managing Director of Xero Australia and Asia, as its new CEO, effective from May 2nd 2022.
As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.
Sky Medical Technology Ltd., an investee company within the Deepbridge Technology Growth EIS portfolio, announced further U.S. Food and Drug Administration (FDA) 510(k) clearance to market the new (W3) geko™ device variant, for increasing microcirculatory blood flow in lower limb soft tissue of patients with venous insufficiency and/or ischemia.
RDVault, an investee company within the Deepbridge Life Sciences EIS portfolio, has won Tech Nation's fourth Rising Stars competition, which recognises the best early-stage technology scale-ups across the UK.
Andrew Aldridge, Partner & Head of Marketing at Deepbridge, recently spoke with Professional Adviser to discuss the UK Government's current tagline of 'Building Back Better' which is focused on the realisation that we all can live in a smarter way and that the UK has the opportunity to be at the forefront of twenty-first century sus
One of Deepbridge Capital's Life Sciences Investment Managers, Ben Carter, recently spoke to IFA Magazine about the role of an investment manager and goes into more detail of the dealflow, networks and sector specific expertise of the Deepbridge Life Sciences EIS portfolio.
Ocutec, which is part of the Deepbridge Technology Growth EIS portfolio, has recently secured £1.5 million in a seed funding round that was led by Deepbridge Capital.
